Article
Survivin Splice Variant 2β Enhances Pancreatic Ductal Adenocarcinoma Resistance to…
OncoTargets and Therapy · 2022 · Fuller RN, Kabagwira J, Vallejos PA, Folkerts AD, Wall NR
Key facts
| Title | Survivin Splice Variant 2β Enhances Pancreatic Ductal Adenocarcinoma Resistance to Gemcitabine |
|---|---|
| First author | Fuller RN, Kabagwira J, Vallejos PA, Folkerts AD, Wall NR |
| Journal | OncoTargets and Therapy |
| Published | Oct 10, 2022 |
| DOI | 10.2147/OTT.S341720 |
| Devices mentioned | 071079, K802418, K810863, K850512, K850524, K973350, K990827 |
| Product codes mentioned | DBM, JLX, KIS, KIT, KQP, NSU |
At a glance
- 1–9 FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1